Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014⁻2016 Outbreak in West Africa.
Adolescent
Adult
Africa, Western
Aged
Antibodies, Viral
/ blood
Child
Child, Preschool
Cytokines
/ genetics
Disease Outbreaks
Ebolavirus
/ genetics
Female
Hemorrhagic Fever, Ebola
/ immunology
Humans
Immunity, Humoral
Inflammation
/ genetics
Interleukins
/ genetics
Male
Middle Aged
Sierra Leone
Survivors
Transcriptome
Viremia
/ epidemiology
Young Adult
antibody
cytokines
ebola virus
immune response
inflammation
sierra leone
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
23 04 2019
23 04 2019
Historique:
received:
05
04
2019
revised:
19
04
2019
accepted:
21
04
2019
entrez:
26
4
2019
pubmed:
26
4
2019
medline:
20
2
2020
Statut:
epublish
Résumé
Ebola virus (EBOV) infection is characterized by an excessive inflammatory response, a loss of lymphocytes and a general paralysis of the immune system, however pathophysiological mechanisms are not fully understood. In a cohort of 23 fatal and 21 survivors of ebola virus disease (EVD) cases admitted to the Emergency Ebola-Treatment-Center in Goderich (Freetown, Sierra Leone) during the 2014 to 2016 EBOV epidemic in Western Africa, we analyzed the pathway-focused gene expression profile of secreted proteins involved in the immune response and the levels of specific anti-EBOV IgM and IgG from the time of admission till discharge or death. We observed a dysregulated inflammatory response in fatal patients as compared to survivors, mainly consisting of the upregulation of inflammatory mediators, whose extent directly correlated with viremia levels. The upregulation persisted and intensified during the late phase of infection. Relevant differences were also found in humoral immunity, as an earlier and more robust EBOV antibody response was observed in survivor patients.
Identifiants
pubmed: 31018522
pii: v11040373
doi: 10.3390/v11040373
pmc: PMC6520887
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Cytokines
0
Interleukins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Références
Vox Sang. 2009 Apr;96(3):183-98
pubmed: 19076338
Blood. 2000 May 15;95(10):3032-43
pubmed: 10807766
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4719-24
pubmed: 25775592
PLoS Negl Trop Dis. 2017 May 30;11(5):e0005645
pubmed: 28558022
BMC Genomics. 2013 May 10;14:319
pubmed: 23663360
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404864
J Clin Invest. 2015 Dec;125(12):4692-8
pubmed: 26551684
Front Microbiol. 2017 Aug 17;8:1571
pubmed: 28861075
Nat Rev Microbiol. 2014 Jun;12(6):426-37
pubmed: 24830471
Nat Microbiol. 2018 Oct;3(10):1084-1089
pubmed: 30150734
Cell Death Dis. 2016 Mar 31;7:e2164
pubmed: 27031961
J Infect Dis. 2017 Apr 1;215(7):1107-1110
pubmed: 28498995
Nature. 2016 May 5;533(7601):100-4
pubmed: 27147028
Cell Host Microbe. 2017 Dec 13;22(6):817-829.e8
pubmed: 29154144
Infect Disord Drug Targets. 2016;16(2):79-94
pubmed: 26743519
Cell. 2014 Oct 23;159(3):477-86
pubmed: 25417101
JCI Insight. 2017 Mar 23;2(6):e88864
pubmed: 28352651
Front Immunol. 2017 Oct 26;8:1372
pubmed: 29123522
J Infect Dis. 1999 Feb;179 Suppl 1:S28-35
pubmed: 9988162
Clin Exp Immunol. 2002 Apr;128(1):163-8
pubmed: 11982604
J Infect Dis. 1999 Feb;179 Suppl 1:S177-87
pubmed: 9988182
Genome Biol. 2017 Jan 19;18(1):4
pubmed: 28100256
Cell Death Differ. 2015 Aug;22(8):1250-9
pubmed: 26024394
Sci Rep. 2017 Jul 20;7(1):6054
pubmed: 28729706
J Infect Dis. 2018 Nov 22;218(suppl_5):S496-S503
pubmed: 30101349
Nat Med. 1999 Apr;5(4):423-6
pubmed: 10202932
Viruses. 2015 Oct 23;7(10):5489-507
pubmed: 26512687
PLoS Negl Trop Dis. 2010 Oct 05;4(10):
pubmed: 20957152
Molecules. 2015 Oct 20;20(10):19030-40
pubmed: 26492230